250 related articles for article (PubMed ID: 9849403)
1. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
Kirkwood JM
Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
4. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Kirkwood JM; Ibrahim J; Lawson DH; Atkins MB; Agarwala SS; Collins K; Mascari R; Morrissey DM; Chapman PB
J Clin Oncol; 2001 Mar; 19(5):1430-6. PubMed ID: 11230488
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
Hillner BE
Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
[TBL] [Abstract][Full Text] [Related]
6. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
7. Intermediate- and high-risk melanoma.
Agarwala SS
Curr Treat Options Oncol; 2002 Jun; 3(3):205-17. PubMed ID: 12057066
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for high-risk primary and resected metastatic melanoma.
Hersey P
Intern Med J; 2003; 33(1-2):33-43. PubMed ID: 12534876
[TBL] [Abstract][Full Text] [Related]
9. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
10. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the care of the patient with malignant melanoma.
Reintgen D; Balch CM; Kirkwood J; Ross M
Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
[TBL] [Abstract][Full Text] [Related]
12. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
Messori A; Becagli P; Trippoli S; Tendi E
Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
[TBL] [Abstract][Full Text] [Related]
14. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
15. Update on adjuvant interferon therapy for high-risk melanoma.
Agarwala SS; Kirkwood JM
Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
[TBL] [Abstract][Full Text] [Related]
17. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
18. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
Mitchell MS; Jakowatz J; Harel W; Dean G; Stevenson L; Boswell WD; Groshen S
J Clin Oncol; 1994 Feb; 12(2):402-11. PubMed ID: 8113848
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
20. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
Donnelly S
Oncol Nurs Forum; 1998 Jun; 25(5):921-7. PubMed ID: 9644709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
